Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.30 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.30 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169496 | 0.71 | SLC22A6 (0.36) | GRIK1GRIK2PMP22BHMTGRIA2 | |
| SCHEMBL15932122 | 0.68 | GRIK1 (0.41) | GRIK1GRIK2BHMTGRIA2GRIA4 | |
| SCHEMBL17921870 | 0.67 | SLC22A6 (0.45) | GRIK1GRIK2BHMTGRIA2GRIA4 | |
| Aspartic Acid SCHEMBL5868261 | 0.66 | PMP22 (0.50) | GRIK1GRIK2PMP22BHMTGRIA2 | |
| Aspartic Acid SCHEMBL5868317 | 0.66 | PMP22 (0.50) | GRIK1GRIK2PMP22BHMTGRIA2 | |
| SCHEMBL3183276 | 0.65 | GRIK1 (0.45) | GRIK1GRIK2BHMTGRIA2GRIA4 | |
| Aspartic Acid SCHEMBL8888023 | 0.65 | GRIK1 (0.48) | GRIK1GRIK2PMP22BHMTGRIA2 | |
| SCHEMBL7407055 | 0.65 | GRIK1 (0.40) | GRIK1GRIK2BHMTGRIA2GRIA4 | |
| SCHEMBL7407058 | 0.65 | GRIK1 (0.40) | GRIK1GRIK2BHMTGRIA2GRIA4 | |
| Aspartic Acid SCHEMBL8888026 | 0.65 | GRIK1 (0.48) | GRIK1GRIK2PMP22BHMTGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | GRIK1 1566/4885GRIK2 1729/4885PMP22 1648/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | GRIK1 1566/4885GRIK2 1729/4885PMP22 1648/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | GRIK1 1814/4885GRIK2 1906/4885PMP22 502/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | GRIK1 1370/4885GRIK2 1363/4885PMP22 773/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | GRIK1 1370/4885GRIK2 1363/4885PMP22 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.